Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

O-004

Supelco

Oxymorphone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C17H19NO4
Numéro CAS:
76-41-5
Poids moléculaire :
301.34
Numéro MDL:
MFCD00079194
Code UNSPSC :
41116107
ID de substance PubChem :
329818813
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

Concentration

1.0 mg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

forensics and toxicology

Format

single component solution

Température de stockage

2-8°C

Chaîne SMILES 

CN1CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@]2(O)CCC4=O)c35

InChI

1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1

Clé InChI

UQCNKQCJZOAFTQ-ISWURRPUSA-N

Informations sur le gène

human ... OPRD1(4985) , OPRK1(4986) , OPRM1(4988)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

A certified Snap-N-Spike® solution of oxymorphone suitable for use in a variety of GC/MS or LC/MS applications from pain prescription monitoring, clinical toxicology, and pharmaceutical research to forensic analysis and urine drug testing. Oxymorphone, sold under trade names such as Opana®, Numorphan®, and Numorphone, is an opiate analgesic indicated for the relief of moderate to severe pain.

Application


  • Advanced UHPLC-MS/MS Methodology: A novel ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method has been developed for quantifying oxymorphone along with other opioids in various human tissues. This technique is crucial for understanding the pharmacokinetics and tissue distribution of synthetic opioids, providing valuable data for both clinical and pharmaceutical research (Manca et al., 2023).

  • Genetic Association Studies: Oxymorphone′s application extends to genetic studies where its interaction with the CYP2D6 genotype is analyzed to determine individual responses in opioid analgesia. This research is critical for optimizing pain management strategies and reducing adverse effects in treatments involving synthetic opioids (Merchant et al., 2022).

  • Drug Safety and Regulation: Oxymorphone is a focus of regulatory review processes, particularly in the context of the opioid crisis. Analyzing the decisions and advisories concerning oxymorphone helps in understanding its role in current medical practice and its impact on public health policies (Litman, 2020).

  • Innovative Analytical Techniques: Research includes the development of advanced analytical techniques, such as gas chromatography-mass spectrometry, for detecting oxymorphone in biological samples. These methods are essential for clinical diagnostics and forensic investigations, ensuring accurate and sensitive detection of this potent analgesic (Norouzi et al., 2020).

  • In Vitro Safety Evaluations: Oxymorphone is also studied in in vitro models to assess its hemolytic potential when abused intravenously. This research is crucial for understanding the risks associated with non-prescribed administration routes and contributes to safer pharmaceutical formulations (Persich et al., 2020).

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Numorphan is a registered trademark of Endo Pharmaceuticals Inc.
Opana is a registered trademark of Endo Pharmaceuticals Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 5

1 of 5

Supelco

Supelco

O-020

Opiate Multi-component Mixture-5 solution

Codeine solution 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-006

Codeine solution

Morphine solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-005

Morphine solution

(±)-MDMA solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-013

(±)-MDMA solution

Buprenorphine solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

B-044

Buprenorphine solution

Wuyi Zha et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 902, 116-121 (2012-07-17)
A selective high performance liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for the simultaneous determination of oxymorphone and its active metabolite 6-OH-oxymorphone in human plasma was developed and validated using oxymorphone-d(3) as the internal standard. Chromatographic conditions were optimized to separate
John H Peniston et al.
Postgraduate medicine, 124(2), 114-122 (2012-03-23)
Opioids and antidepressants are frequently prescribed for chronic low back pain (cLBP). This post hoc analysis was conducted to assess the tolerability of oxymorphone extended release (ER) for cLBP in patients taking selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake
Joseph V Pergolizzi et al.
Journal of opioid management, 8(6), 383-393 (2012-12-25)
The aging population generally has greater need for analgesics and is best served by having as many good therapeutic options as possible. Geriatric analgesia requires special consideration of age-associated physiologic changes that can affect drug dosing. The study of extended-release
Marco Pappagallo et al.
Postgraduate medicine, 124(5), 101-109 (2012-10-26)
Because rates of both opioid prescribing and opioid abuse have increased, drug companies have responded by considering strategies to make opioid formulations less attractive for abuse without compromising safety or efficacy for patients with legitimate pain management needs. The emergence
M Spetea et al.
Current medicinal chemistry, 19(15), 2442-2457 (2012-03-30)
Morphine and other opioid morphinans produce analgesia primarily through μ opioid receptors (MORs), which mediate beneficial but also non-beneficial actions. There is a continued search for efficacious opioid analgesics with reduced complications. The cornerstone in the development of 14-alkoxymorphinans as
Afficher tous les articles scientifiques apparentés

Articles

Benefits of Ascentis Express Phenyl-Hexyl over Biphenyl for the Separation of Pain Management Opiates

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Protocoles

LC/MS (TOF) Analysis of Drugs and Their Glucuronide Metabolites in Urine on Titan™ C18 after Solid Phase Extraction (SPE) using Supel™-Select SCX, β-Glucuronidase Enzyme Digestion

-THC solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

Using UHPLC/MS (TOF) for Detection of Drugs and Metabolites in Urine Following Optimized Enzymatic Hydrolysis Conditions

To optimize hydrolysis using β-glucuronidase, factors such as incubation time, temperature, hydrolysis pH, enzyme source, and enzyme concentration must be evaluated for each glucuronide metabolite to be analyzed.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique